论文部分内容阅读
目的:比较玻璃体切除术前不同剂量雷珠单抗玻璃体内注射治疗增生性糖尿病性视网膜病变(PDR)的效果。方法:前瞻性研究。选取郑州市第二人民医院2018年1月至2019年4月就诊的PDR患者80例(80眼)。随机分为3组：单纯玻璃体切除组，30例；标准剂量组，30例；术前应用0.25 mg/0.025 ml雷珠单抗半剂量组，20例，术前3～5天应用0.5 mg/0.5 ml雷珠单抗。术后随访6个月，观察视力、手术耗时及并发症情况。结果:单纯手术组、标准剂量组和半剂量组平均手术耗时依次为(60.2±7.8)min、(43.5±10.1)min和(43.0±6.4)min；三组术后视力(logMAR)依次为1.13±0.48、1.08±0.65和1.07±0.72；术中三组依次有6例、1例和0例使用玻璃体填充物；依次有11例、3例和2例再次玻璃体积血；单纯手术组中7例再次手术，1例出现新生血管性青光眼。结论:玻璃体切除术前应用0.25 mg与0.5 mg雷珠单抗均可缩短手术时间，减少手术并发症。“,”Objective:To compare the efficacy of intravitreal injection of different doses of ranibizumab before vitrectomy for proliferative diabetic retinopathy (PDR).Methods:This was a prospective study. A total of 80 eyes of 80 cases with PDR from Jan. 2018 to Apr. 2019 in Zhengzhou Second People’s Hospital were randomly divided into three groups. There were 30 cases in the single vitrectomy group. The standard dosage group with 30 cases were given 0.5 mg/0.05 ml ranibizumab 3-5 days before PPV, while the half dosage group with 20 cases were given 0.25 mg/0.025 ml ranibizumab. All patients were followed up for 6 months. BCVA, operation duration, and complications were observed.Results:The average operation duration was (60.2±7.8) minutes, (43.5±10.1) minutes and (43.0±6.4) minutes in the simple surgery group, the standard dosage group and the half dosage group respectively. Postoperative BCVA (logMAR) was 1.13±0.48, 1.08±0.65 and 1.07±0.72 of three groups in turn. Vitreous tamponade was used in 6 cases, 1 case and 0 of the three groups in turn. There were 11 cases of the simple surgery group, 3 cases of standard dosage group and 2 cases of half dosage group who had recurrent vitreous hemorrhage. Seven cases in the simple surgery group received vitreous lavage again, and 1 case had neovascular glaucoma.Conclusion:Intravitreal injection of ranibizumab with 0.25 mg and 0.5 mg before vitrectomy both can shorten the operation duration and reduce the incidence of complications of PPV.